| Comparison 1: Usual care versus immunosuppressive withdrawal after monotherapy |
|
| Outcome |
Random Effects RR (95% CI) |
Fixed Effect RR (95% CI) |
Impact |
| 1.1 Relapse at 12, 18 or 24 months |
0.42 (0.24‐0.72) |
0.42 (0.24‐0.72) |
No change |
| 1.2 New CD‐related complications |
0.34 (0.06‐2.08) |
0.34 (0.06‐2.08) |
No change |
| 1.3 Adverse events |
0.88 (0.67‐1.17) |
0.97 (0.71‐1.32) |
Minimal |
| 1.4 Serious adverse events |
3.29 (0.35‐30.80) |
3.29 (0.35‐30.80) |
No change |
| 1.5 Withdrawal due to adverse events |
2.59 (0.35‐19.04) |
3.10 (0.49‐19.41) |
Minimal |
| Comparison 2: Usual care versus Immunosuppressive withdrawal after combination therapy |
|
| Outcome |
Random Effects RR (95% CI) |
Fixed Effect RR (95% CI) |
|
| 2.1 Relapse at 12 or 24 months |
1.02 (0.68‐1.52) |
0.99 (0.69‐1.43) |
Minimal |
| 2.2 Adverse events |
1.11 (0.44‐2.81) |
1.04 (0.73‐1.47) |
Minimal |
| 2.3 Serious adverse events |
No pooling |
No pooling |
No pooling |
